Neuland Laboratories Share Price
Sector: Major Drugs
You have to be logged in to add this to Watchlist.
Login or Register
15352.15 -956.40 (-5.86%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
15320.75
Today’s High
16259.95
52 Week Low
3612.05
52 Week High
16501
15441.15 -809.55 (-4.98%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
15350
Today’s High
16249.95
52 Week Low
3611.1
52 Week High
16524.95
Key Metrics
- Market Cap (In Cr) 20849.47
- Beta 1.3
- Div. Yield (%) 0.09
- P/B 16.25
- TTM P/E 28.57
- Peg Ratio -4.96
- Sector P/E 32.9
- D/E -
- Open Price 16200.05
- Prev Close 16308.55
Neuland Laboratories Analysis
Price Analysis
-
1 Week37.65%
-
3 Months91.58%
-
6 Month115.82%
-
YTD207.12%
-
1 Year304.66%
Risk Meter
- 57% Low risk
- 57% Moderate risk
- 57% Balanced Risk
- 57% High risk
- 57% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 1
- 1
- 1
- Buy
- 1
- 1
- 1
- 1
- Hold
- 0
- 0
- 0
- 0
- Sell
- 0
- 0
- 0
- 0
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 2
- 2
- 2
- 2
Neuland Laboratories News
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
1 min read . 14 Oct 2024Praj Industries, NOCIL, Affle India and more: B&K lists top 10 stock picks for July
6 min read . 02 Jul 2024Neuland Laboratories crack 13.5% as Q4 results miss Street expectations
2 min read . 13 May 2024Neuland Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 1558.58
- Selling/ General/ Admin Expenses Total
- 257.06
- Depreciation/ Amortization
- 59.7
- Other Operating Expenses Total
- 105.13
- Total Operating Expense
- 1155.69
- Operating Income
- 402.89
- Net Income Before Taxes
- 401.44
- Net Income
- 300.08
- Diluted Normalized EPS
- 233.89
- Period
- 2024
- Total Assets
- 1832.56
- Total Liabilities
- 549.86
- Total Equity
- 1282.7
- Tangible Book Valueper Share Common Eq
- 780.04
- Period
- 2024
- Cashfrom Operating Activities
- 261.18
- Cashfrom Investing Activities
- -149.69
- Cashfrom Financing Activities
- -69.28
- Net Changein Cash
- 42.16
- Period
- 2023
- Total Revenue
- 1191.2
- Selling/ General/ Admin Expenses Total
- 277.38
- Depreciation/ Amortization
- 52.46
- Other Operating Expenses Total
- 5.35
- Total Operating Expense
- 960.93
- Operating Income
- 230.27
- Net Income Before Taxes
- 215.75
- Net Income
- 163.52
- Diluted Normalized EPS
- 127.96
- Period
- 2023
- Total Assets
- 1579.76
- Total Liabilities
- 585.67
- Total Equity
- 994.1
- Tangible Book Valueper Share Common Eq
- 555.99
- Period
- 2023
- Cashfrom Operating Activities
- 237.21
- Cashfrom Investing Activities
- -61.5
- Cashfrom Financing Activities
- -135.8
- Net Changein Cash
- 40.32
- Period
- 2022
- Total Revenue
- 951.08
- Selling/ General/ Admin Expenses Total
- 253.11
- Depreciation/ Amortization
- 48.78
- Other Operating Expenses Total
- 5.63
- Total Operating Expense
- 855.59
- Operating Income
- 95.49
- Net Income Before Taxes
- 82.16
- Net Income
- 63.82
- Diluted Normalized EPS
- 50.84
- Period
- 2022
- Total Assets
- 1383.49
- Total Liabilities
- 542.99
- Total Equity
- 840.5
- Tangible Book Valueper Share Common Eq
- 435.64
- Period
- 2022
- Cashfrom Operating Activities
- 60.39
- Cashfrom Investing Activities
- -95.52
- Cashfrom Financing Activities
- 37.72
- Net Changein Cash
- 2.66
- Period
- 2021
- Total Revenue
- 936.91
- Selling/ General/ Admin Expenses Total
- 117.87
- Depreciation/ Amortization
- 39.68
- Other Operating Expenses Total
- 4.9
- Total Operating Expense
- 827.34
- Operating Income
- 109.58
- Net Income Before Taxes
- 105.33
- Net Income
- 80.63
- Diluted Normalized EPS
- 63.01
- Period
- 2021
- Total Assets
- 1324.79
- Total Liabilities
- 538.33
- Total Equity
- 786.46
- Tangible Book Valueper Share Common Eq
- 392.44
- Period
- 2021
- Cashfrom Operating Activities
- 189.36
- Cashfrom Investing Activities
- -84.42
- Cashfrom Financing Activities
- -113.66
- Net Changein Cash
- -8.77
- Period
- 2020
- Total Revenue
- 762.71
- Selling/ General/ Admin Expenses Total
- 191.03
- Depreciation/ Amortization
- 31.28
- Other Operating Expenses Total
- 3.98
- Total Operating Expense
- 690.43
- Operating Income
- 72.28
- Net Income Before Taxes
- 52.92
- Net Income
- 16.21
- Diluted Normalized EPS
- 30.53
- Period
- 2020
- Total Assets
- 1230.98
- Total Liabilities
- 521.02
- Total Equity
- 709.96
- Tangible Book Valueper Share Common Eq
- 334.02
- Period
- 2020
- Cashfrom Operating Activities
- 57.34
- Cashfrom Investing Activities
- -48.68
- Cashfrom Financing Activities
- -5.48
- Net Changein Cash
- 3.27
- Period
- 2019
- Total Revenue
- 666.83
- Selling/ General/ Admin Expenses Total
- 161.42
- Depreciation/ Amortization
- 25.86
- Other Operating Expenses Total
- 3.74
- Total Operating Expense
- 629
- Operating Income
- 37.83
- Net Income Before Taxes
- 20.34
- Net Income
- 16.44
- Diluted Normalized EPS
- 13.15
- Period
- 2019
- Total Assets
- 1130.35
- Total Liabilities
- 431.04
- Total Equity
- 699.31
- Tangible Book Valueper Share Common Eq
- 325.83
- Period
- 2019
- Cashfrom Operating Activities
- 69.91
- Cashfrom Investing Activities
- -77.23
- Cashfrom Financing Activities
- 11.98
- Net Changein Cash
- 4.65
- Period
- 2018
- Total Revenue
- 529.16
- Selling/ General/ Admin Expenses Total
- 155.17
- Depreciation/ Amortization
- 22.1
- Other Operating Expenses Total
- 5.52
- Total Operating Expense
- 500.16
- Operating Income
- 29.01
- Net Income Before Taxes
- 13.93
- Net Income
- 12.06
- Diluted Normalized EPS
- 10.94
- Period
- 2018
- Total Assets
- 1071.39
- Total Liabilities
- 513.35
- Total Equity
- 558.04
- Tangible Book Valueper Share Common Eq
- 311.56
- Period
- 2018
- Cashfrom Operating Activities
- 11.27
- Cashfrom Investing Activities
- -116.29
- Cashfrom Financing Activities
- 104.85
- Net Changein Cash
- -0.16
- Period
- 2024-06-30
- Total Revenue
- 439.6
- Selling/ General/ Admin Expenses Total
- 73.14
- Depreciation/ Amortization
- 16.28
- Other Operating Expenses Total
- 30.07
- Total Operating Expense
- 311.9
- Operating Income
- 127.71
- Net Income Before Taxes
- 129.84
- Net Income
- 97.87
- Diluted Normalized EPS
- 64.16
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 385.01
- Selling/ General/ Admin Expenses Total
- 62.49
- Depreciation/ Amortization
- 16.46
- Other Operating Expenses Total
- 35.58
- Total Operating Expense
- 294.56
- Operating Income
- 90.45
- Net Income Before Taxes
- 92.2
- Net Income
- 67.56
- Diluted Normalized EPS
- 52.66
- Period
- 2024-03-31
- Total Assets
- 1832.56
- Total Liabilities
- 549.86
- Total Equity
- 1282.7
- Tangible Book Valueper Share Common Eq
- 780.04
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 261.18
- Cashfrom Investing Activities
- -149.69
- Cashfrom Financing Activities
- -69.28
- Net Changein Cash
- 42.16
- Period
- 2023-12-31
- Total Revenue
- 392.83
- Selling/ General/ Admin Expenses Total
- 65.73
- Depreciation/ Amortization
- 15.14
- Other Operating Expenses Total
- 27.24
- Total Operating Expense
- 286.71
- Operating Income
- 106.12
- Net Income Before Taxes
- 104.48
- Net Income
- 81.39
- Diluted Normalized EPS
- 63.44
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 417.75
- Selling/ General/ Admin Expenses Total
- 68.96
- Depreciation/ Amortization
- 14.51
- Other Operating Expenses Total
- 19.72
- Total Operating Expense
- 294.77
- Operating Income
- 122.98
- Net Income Before Taxes
- 121.59
- Net Income
- 89.25
- Diluted Normalized EPS
- 69.56
- Period
- 2023-09-30
- Total Assets
- 1665.06
- Total Liabilities
- 532.28
- Total Equity
- 1132.78
- Tangible Book Valueper Share Common Eq
- 660.06
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 164.94
- Cashfrom Investing Activities
- -37.81
- Cashfrom Financing Activities
- -47.5
- Net Changein Cash
- 79.59
- Period
- 2023-06-30
- Total Revenue
- 362.99
- Selling/ General/ Admin Expenses Total
- 59.89
- Depreciation/ Amortization
- 13.59
- Other Operating Expenses Total
- 22.58
- Total Operating Expense
- 279.66
- Operating Income
- 83.33
- Net Income Before Taxes
- 83.16
- Net Income
- 61.88
- Diluted Normalized EPS
- 48.23
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 407.07
- Selling/ General/ Admin Expenses Total
- 49.53
- Depreciation/ Amortization
- 13.47
- Other Operating Expenses Total
- 29.03
- Total Operating Expense
- 300.68
- Operating Income
- 106.39
- Net Income Before Taxes
- 110.16
- Net Income
- 84.54
- Diluted Normalized EPS
- 65.91
- Period
- 2023-03-31
- Total Assets
- 1579.76
- Total Liabilities
- 585.67
- Total Equity
- 994.1
- Tangible Book Valueper Share Common Eq
- 555.99
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 237.21
- Cashfrom Investing Activities
- -61.5
- Cashfrom Financing Activities
- -135.8
- Net Changein Cash
- 40.32
- Period
- 2022-12-31
- Total Revenue
- 269.25
- Selling/ General/ Admin Expenses Total
- 51.62
- Depreciation/ Amortization
- 13.34
- Other Operating Expenses Total
- 24.11
- Total Operating Expense
- 228.5
- Operating Income
- 40.75
- Net Income Before Taxes
- 38.94
- Net Income
- 30.55
- Diluted Normalized EPS
- 23.81
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Neuland Laboratories Technical
Moving Average
SMA
- 5 Day13699.05
- 10 Day12818.17
- 20 Day12730.97
- 50 Day12236.37
- 100 Day9720.5
- 300 Day8057.91
Neuland Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Aurobindo Pharma
- 1466
- -16.7
- -1.13
- 1592.55
- 834.9
- 85892.94
- Pfizer
- 5787.05
- 92.6
- 1.63
- 6452.85
- 3834.4
- 26474.44
- Neuland Laboratories
- 15352.15
- -956.4
- -5.86
- 16501
- 3612.05
- 19696.64
- Astrazeneca Pharma India
- 7623.15
- -8.25
- -0.11
- 8139.85
- 4050.15
- 19057.88
- Unichem Laboratories
- 725.9
- -2.6
- -0.36
- 755.15
- 398.7
- 5110.75
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Aurobindo Pharma
- 25.97
- 2.91
- 14.22
- 12.72
- Pfizer
- 48.15
- 7.33
- 18.43
- 24.05
- Neuland Laboratories
- 63.05
- 15.65
- 14.98
- 11.99
- Astrazeneca Pharma India
- 126.67
- 26.74
- 20.1
- 10.27
- Unichem Laboratories
- -
- 2.22
- -2.1
- -3.99
Neuland Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 01-Aug-24
- Quarterly Results
- 10-May-24
- Audited Results & Final Dividend
- 08-Feb-24
- Quarterly Results
- 07-Nov-23
- Quarterly Results
- 03-Aug-23
- Quarterly Results
- 11-May-23
- Audited Results & Final Dividend
- 13-Feb-23
- Quarterly Results
- 10-Nov-22
- Quarterly Results
- 03-Aug-22
- Quarterly Results
- 10-May-22
- Audited Results & Final Dividend
- Meeting Date
- Announced on
- Purpose
- 31-Jul-24
- 10-May-24
- AGM
- 27-Jul-23
- 11-May-23
- AGM
- 02-Aug-22
- 17-Jun-22
- AGM
- 07-Jul-21
- 07-Jun-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 10-May-24
- -
- 12-Jul-24
- 14
- 11-May-23
- -
- 11-Jul-23
- 10
- 10-May-22
- 15-Jul-22
- 14-Jul-22
- 5
- 11-May-21
- -
- 29-Jun-21
- 3